Last reviewed · How we verify

NCT05335655

IV Dexmedetomidine in the Duration of Spinal Anesthesia With Hyperbaric Bupivacaine: Double Blind Randomized Trial.

Status unknown Phase 3 Last updated 13 June 2022
What this trial tests

Phase 3 trial testing Dexmedetomidine injection in Anesthesia in 60 participants. Status unknown.

Timeline
31 January 2022
Primary endpoint
10 June 2022
15 June 2022

Quick facts

Lead sponsorHospital Central "Dr. Ignacio Morones Prieto"
PhasePhase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposesupportive care
Enrollment60
Start date31 January 2022
Primary completion10 June 2022
Estimated completion15 June 2022
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Central "Dr. Ignacio Morones Prieto"

Who can join

Adults 18 to 65, any sex, with Anesthesia or Dexmedetomidine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction: Spinal anesthesia produces sensitive and motor block according to the administered local anesthetic. The total duration of surgical anesthesia depends on the dose, intrinsic properties of the anesthetic, and the use of additional drugs. Dexmedetomidine is an alpha-2 adrenergic agonist that has sedative and analgesic effects. The specific action site in the spinal cord receptors and in the locus coeruleus provide as well hypnotic and sympatholytic characteristics. The combination of spinal anesthesia and intravenous dexmedetomidine is a safe option for hemodynamically stable patients undergoing elective surgery. Material and methods: Double blind randomized trial. The objective is to time and compare the total duration of neuraxial blockade with spinal hyperbaric bupivacaine plus intravenous dexmedetomidine, against hyperbaric bupivacaine by itself. 60 patients shall be included, between the ages of 18 and 65 years, classified by the American Society of Anesthesiologists (ASA) I and II, undergoing lower limb elective orthopedic procedure, with spinal anesthesia plus epidural catheter. 50% of the patients (group A) will receive spinal hyperbaric bupivacaine and IV dexmedetomidine at 0.5 mcg/kg (real weight), and the other 50% (group B) will receive spinal hyperbaric bupivacaine plus IV 0.9% saline solution in equivalent volume.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dexmedetomidine injection

Trials testing the same drug.

Other recruiting trials for Anesthesia

Currently open trials in the same condition.

Other Hospital Central "Dr. Ignacio Morones Prieto" trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05335655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing